AstraZeneca has announced a new $1.5 billion facility that it is planning to build in Singapore for manufacturing antibody drug conjugates (ADCs). The Singapore Economic Development Board (EDB) has offered its support to the new facility, which will be AstraZeneca's first end-to-end ADC production site. Source: Biopharm International 21/5/2024